Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report

Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Market Research Report (2017-2028)

  • POSTDATE：Nov 09, 2022
  • PAGES：192
  • REPORT CODE：GMM1359500
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Duchenne Muscular Dystrophy (DMD) Therapeutics industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions along with the strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    Please note that the figures and tables shown in the sample are just for the purpose of demonstration, which may differ from those in the final report.

    Competitive Landscape:

    • Sarepta Therapeutics Inc

    • F Hoffmann-La Roche Ltd

    • Italfarmaco

    • Wave Life Sciences Ltd

    • PTC Therapeutics Inc

    Region:

    • China

    • North America

    • Europe

    • APAC

    • Latin America, Middle East and Africa

    Type:

    • Pain Management Drugs

    • Corticosteroids

    • Prednisone

    • Deflazacort

    • Others

    Application:

    • Hospitals

    • Clinics

    • Home Care

  • Table of Content

    Chapter 1 Industry Overview & Development Status in Global and China Market

    • 1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Overview

      • 1.1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Scope and Market Segments

      • 1.1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Characteristics

      • 1.1.3 Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

      • 1.1.4 Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Production Value and Growth Rate (2017-2028)

    • 1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate by Type (2017-2028)

      • 1.2.1 Pain Management Drugs

      • 1.2.2 Corticosteroids

      • 1.2.3 Prednisone

      • 1.2.4 Deflazacort

      • 1.2.5 Others

    • 1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate by Application (2017-2028)

      • 1.3.1 Hospitals

      • 1.3.2 Clinics

      • 1.3.3 Home Care

    • 1.4 Market Analysis by Region

      • 1.4.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Market Size and Growth Rate (2017-2028)

      • 1.4.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Market Size and Growth Rate (2017-2028)

      • 1.4.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Market Size and Growth Rate (2017-2028)

      • 1.4.4 Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Market Size and Growth Rate (2017-2028)

    • 1.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)

      • 1.5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)

    • 1.6 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Price, Sales Value (2017-2028)

      • 1.6.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Price, Sales Value (2017-2028)

    Chapter 2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Challenges and Restraints

      • 2.1.2 Opportunities and Potentialities

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape

      • 2.2.1 Market Concentration Rate Analysis

      • 2.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Porter's Five Forces Model Analysis

      • 2.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry PEST Analysis

    • 2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Chain Analysis

      • 2.3.1 Raw Material Supplies

      • 2.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Downstream Market Analysis

      • 2.3.3 Upstream and Downstream Impacts on Duchenne Muscular Dystrophy (DMD) Therapeutics Industry

    Chapter 3 Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Manufacturer

    • 3.1 Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Market Share, by Manufacturer (2021&2022)

      • 3.1.1 Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Manufacturer (2021&2022)

      • 3.1.2 Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Manufacturer (2021&2022)

      • 3.1.3 Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share, by Manufacturer (2021&2022)

    • 3.2 SWOT Analysis on Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Top 3 Players

    Chapter 4 Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Type (2017-2028)

    • 4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trend, by Type

    • 4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value, Market Share and Price Trend, by Type

      • 4.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Market Share, by Type (2017-2028)

      • 4.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Market Share, by Type (2017-2028)

      • 4.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Price Trend, by Type (2017-2028)

    • 4.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value, Market Share and Price Trend, by Type

      • 4.3.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Market Share, by Type (2017-2028)

      • 4.3.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Market Share, by Type (2017-2028)

      • 4.3.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Price Trend, by Type (2017-2028)

    Chapter 5 Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Application (2017-2028)

    • 5.1 Downstream Market Overview

    • 5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Market Share, by Application

      • 5.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Market Share, by Application (2017-2028)

      • 5.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Market Share, by Application (2017-2028)

    • 5.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Market Share, by Application

      • 5.3.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Market Share, by Application (2017-2028)

      • 5.3.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Market Share, by Application (2017-2028)

    Chapter 6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export, by Region (2017-2022)

    • 6.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export (2017-2022)

    • 6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export (2017-2022)

    • 6.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export (2017-2022)

    • 6.4 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export (2017-2022)

    • 6.5 Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export (2017-2022)

    Chapter 7 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis

    • 7.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Type

    • 7.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Application

    • 7.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Forecast, by Country

      • 7.3.1 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 7.3.2 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 7.3.3 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 8 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis

    • 8.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Type

    • 8.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Application

    • 8.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Forecast, by Country

      • 8.3.1 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.2 UK Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.3 France Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.4 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.5 Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.6 Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.7 Belgium Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.8 Poland Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.9 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.10 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 9 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis

    • 9.1 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Type

    • 9.2 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Application

    • 9.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Forecast, by Country

      • 9.3.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.2 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.3 Australia and New Zealand Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.4 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.5 ASEAN Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.6 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 10 Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis

    • 10.1 Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Type

    • 10.2 Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, by Application

    • 10.3 Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Forecast, by Country

      • 10.3.1 GCC Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.2 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.3 Nigeria Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.4 South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.5 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 11 Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Company Profiles

      • 11.1 Sarepta Therapeutics Inc

        • 11.1.1 Sarepta Therapeutics Inc Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.1.2 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Product Profiles, Application and Specification

        • 11.1.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.2 F Hoffmann-La Roche Ltd

        • 11.2.1 F Hoffmann-La Roche Ltd Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.2.2 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Product Profiles, Application and Specification

        • 11.2.3 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.3 Italfarmaco

        • 11.3.1 Italfarmaco Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.3.2 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Profiles, Application and Specification

        • 11.3.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.4 Wave Life Sciences Ltd

        • 11.4.1 Wave Life Sciences Ltd Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.4.2 Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Product Profiles, Application and Specification

        • 11.4.3 Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.5 PTC Therapeutics Inc

        • 11.5.1 PTC Therapeutics Inc Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.5.2 PTC Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Product Profiles, Application and Specification

        • 11.5.3 PTC Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    Chapter 12 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Investment Prospect and Risk Assessment

    • 12.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Investment Prospect Assessment

      • 12.1.1 Investment Opportunities in Segmented Markets

      • 12.1.2 Investment Opportunities in Regional Markets

      • 12.1.3 Investment Opportunities in Subdivided Industries

    • 12.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Investment Risk Assessment

      • 12.2.1 Competitive Risk Analysis

      • 12.2.2 Technology Risk Analysis

      • 12.2.3 Policies and Enterprise System Risk Analysis

    List of Tables and Figures

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Production Value and Growth Rate (2017-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Production Value and Growth Rate (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate of Pain Management Drugs (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate of Corticosteroids (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate of Prednisone (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate of Deflazacort (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate of Others (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate of Hospitals (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate of Clinics (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate of Home Care (2017-2028)

    • Figure North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Market Size and Growth Rate (2017-2028)

    • Figure Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Market Size and Growth Rate (2017-2028)

    • Figure APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Market Size and Growth Rate (2017-2028)

    • Figure Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Market Size and Growth Rate (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Price, Sales Value (2017-2028)

    • Figure Porter's Five Forces Model Analysis

    • Figure Industry PEST Analysis

    • Table Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Manufacturer (2021&2022)

    • Table Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Manufacturer (2021&2022)

    • Table Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share, by Manufacturer (2021&2022)

    • Figure Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share, by Manufacturer in 2021

    • Figure Global and China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share, by Manufacturer in 2022

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Type (2017-2028)

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Type (2017-2028)

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share, by Type (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Price Trend, by Type (2017-2028)

    • Table China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Type (2017-2028)

    • Table China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Type (2017-2028)

    • Table China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share, by Type (2017-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Price Trend, by Type (2017-2028)

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Application (2017-2028)

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Application (2017-2028)

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share, by Application (2017-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share, by Application (2017-2028)

    • Table China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Application (2017-2028)

    • Table China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Table China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Application (2017-2028)

    • Table China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share, by Application (2017-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Share, by Application (2017-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export (2017-2022)

    • Figure North America Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export (2017-2022)

    • Figure Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export (2017-2022)

    • Figure APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export (2017-2022)

    • Figure Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Production, Import, Consumption and Export (2017-2022)

    • Table North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Type (2017-2028)

    • Table North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Application (2017-2028)

    • Table North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Table Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Type (2017-2028)

    • Table Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Application (2017-2028)

    • Table Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure UK Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure UK Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure France Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure France Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Belgium Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Belgium Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Poland Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Poland Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Table APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Type (2017-2028)

    • Table APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Application (2017-2028)

    • Table APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Australia and New Zealand Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Australia and New Zealand Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure ASEAN Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure ASEAN Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Table Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Type (2017-2028)

    • Table Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Figure Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Type (2017-2028)

    • Table Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, by Application (2017-2028)

    • Table Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure Latin America, Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume Share, by Application (2017-2028)

    • Figure GCC Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure GCC Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Nigeria Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Nigeria Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Figure Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume and Growth Rate (2017-2028)

    • Figure Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value and Growth Rate (2017-2028)

    • Table Sarepta Therapeutics Inc Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Sarepta Therapeutics Inc Product Profiles, Application and Specification

    • Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table F Hoffmann-La Roche Ltd Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table F Hoffmann-La Roche Ltd Product Profiles, Application and Specification

    • Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Italfarmaco Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Italfarmaco Product Profiles, Application and Specification

    • Table Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Wave Life Sciences Ltd Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Wave Life Sciences Ltd Product Profiles, Application and Specification

    • Table Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table PTC Therapeutics Inc Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table PTC Therapeutics Inc Product Profiles, Application and Specification

    • Table PTC Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US